Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 1/20 | 0.52 |
| ▸ | CA1 | P00915 | 1/20 | 0.52 |
| ▸ | CA2 | P00918 | 1/20 | 0.52 |
| ▸ | CA7 | P43166 | 1/20 | 0.52 |
| ▸ | CA9 | Q16790 | 1/20 | 0.52 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.52 |
| ▸ | CTSD | P07339 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | HPGD | P15428 | 2/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20790009 | 0.89 | KCNK3 (0.46) | CA12CA1CA2CA7CA9 | |
| SCHEMBL31445291 | 0.88 | CA12 (0.44) | CA12CA1CA2CA7CA9 | |
| SCHEMBL20789996 | 0.85 | KCNK3 (0.47) | CA12CA1CA2CA7CA9 | |
| SCHEMBL31445862 | 0.84 | PDE4D (0.43) | CA12CA1CA2CA7CA9 | |
| SCHEMBL20789990 | 0.84 | PDE4B (0.44) | CA12CA1CA2CA7CA9 | |
| SCHEMBL20790239 | 0.83 | CA12 (0.46) | CA12CA1CA2CA7CA9 | |
| SCHEMBL20790080 | 0.82 | MEN1 (0.44) | CA12CA1CA2CA7CA9 | |
| SCHEMBL1465128 | 0.81 | SIGMAR1 (0.50) | CA12CA1CA2CA7CA9 | |
| SCHEMBL20819588 | 0.81 | ALDH1A1 (0.45) | CA12CA1CA2CA7CA9 | |
| SCHEMBL20790295 | 0.81 | LMNA (0.40) | CA12CA1CA2CA7CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3865474-A1 | MODULATORS OF THE CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR PROTEIN AND METHODS OF USE | AbbVie Overseas S.à r.l. (LU) | 2021-08-18 | — | — | EP | disclosed |
| US-20210238159-A1 | Modulators of the Cystic Fibrosis Transmembrane Conductance Regulator Protein and Methods of Use | ABBVIE GLOBAL LIMITED (BM) | 2021-08-05 | — | — | US | disclosed |
| EP-3736270-B1 | MODULATORS OF THE CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR PROTEIN AND METHODS OF USE | ABBVIE OVERSEAS SARL (LU) | 2021-05-05 | — | — | EP | disclosed |
| EP-3736267-B1 | MODULATORS OF THE CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR PROTEIN AND METHODS OF USE | ABBVIE OVERSEAS SARL (LU) | 2021-05-05 | — | — | EP | disclosed |
| US-10988454-B2 | Modulators of the cystic fibrosis transmembrane conductance regulator protein and methods of use | ABBVIE OVERSEAS S.À.R.L. (LU) | 2021-04-27 | — | — | US | disclosed |
| US-10981890-B2 | Modulators of the cystic fibrosis transmembrane conductance regulator protein and methods of use | ABBVIE OVERSEAS S.À.R.L. (LU) | 2021-04-20 | — | — | US | disclosed |
| US-10844041-B2 | Modulators of the cystic fibrosis transmembrane conductance regulator protein and methods of use | ABBVIE OVERSEAS S.À.R.L. (LU) | 2020-11-24 | — | — | US | disclosed |
| US-10844042-B2 | Modulators of the cystic fibrosis transmembrane conductance regulator protein and methods of use | ABBVIE OVERSEAS S.À.R.L. (LU) | 2020-11-24 | — | — | US | disclosed |
| CN-111954664-A | Cystic fibrosis transmembrane conductance regulator and methods of use | 艾伯维海外有限公司 | 2020-11-17 | — | — | CN | disclosed |
| EP-3736267-A1 | MODULATORS OF THE CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR PROTEIN AND METHODS OF USE | AbbVie Overseas S.à r.l. (LU) | 2020-11-11 | — | — | EP | disclosed |
| EP-1885722-B1 | QUINOLINE DERIVATIVES AS EP4 ANTAGONISTS | MERCK CANADA INC (CA) | 2011-11-16 | — | — | EP | disclosed |
| US-20110262430-A1 | NOVEL ANTIBODIES | ELLIS JONATHAN HENRY | 2011-10-27 | — | — | US | disclosed |
| US-8013159-B2 | Quinoline derivatives as EP4 antagonists | MERCK CANADA INC. (CA) | 2011-09-06 | — | — | US | disclosed |
| US-8013159-B2 | Quinoline derivatives as EP4 antagonists | MERCK CANADA INC. (CA) | 2011-09-06 | — | — | US | disclosed |
| US-8013159-B2 | Quinoline derivatives as EP4 antagonists | MERCK CANADA INC. (CA) | 2011-09-06 | — | — | US | disclosed |
| US-20090099226-A1 | Quinoline derivatives as ep4 antagonists | MERCK CANADA INC. (CA) | 2009-04-16 | — | — | US | disclosed |
| US-20090099226-A1 | Quinoline derivatives as ep4 antagonists | MERCK CANADA INC. (CA) | 2009-04-16 | — | — | US | disclosed |
| US-20090099226-A1 | Quinoline derivatives as ep4 antagonists | MERCK CANADA INC. (CA) | 2009-04-16 | — | — | US | disclosed |
| EP-1885722-A1 | QUINOLINE DERIVATIVES AS EP4 ANTAGONISTS | Merck Frosst Canada Ltd. (CA) | 2008-02-13 | — | — | EP | disclosed |
| WO-2006122403-A1 | QUINOLINE DERIVATIVES AS EP4 ANTAGONISTS | MERCK FROSST CANADA LTD. (CA) | 2006-11-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210238159-A1 | Modulators of the Cystic Fibrosis Transmembrane Conductance Regulator Protein and Methods of Use | CFTR, SLC47A1, SCNN1A | CA12 4400/4885CA1 4846/4885CA2 1799/4885 |
| US-10844042-B2 | Modulators of the cystic fibrosis transmembrane conductance regulator protein and methods of use | CFTR, SLC47A1, SCNN1A | CA12 4400/4885CA1 4846/4885CA2 1799/4885 |
| US-10988454-B2 | Modulators of the cystic fibrosis transmembrane conductance regulator protein and methods of use | CFTR, SLC47A1, SCNN1A | CA12 4400/4885CA1 4846/4885CA2 1799/4885 |
| US-10844041-B2 | Modulators of the cystic fibrosis transmembrane conductance regulator protein and methods of use | CFTR, SLC47A1, SCNN1A | CA12 4400/4885CA1 4846/4885CA2 1799/4885 |
| US-10981890-B2 | Modulators of the cystic fibrosis transmembrane conductance regulator protein and methods of use | CFTR, SLC47A1, SCNN1A | CA12 4400/4885CA1 4846/4885CA2 1799/4885 |
| US-20090099226-A1 | Quinoline derivatives as ep4 antagonists | PTGER4, PTGER1, PTGER3 | CA12 3099/4885CA1 2636/4885CA2 1459/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.